Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

Mineralys Is In A Close Race With AstraZeneca

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Mineralys Therapeutics
Mineralys Therapeutics (Shutterstock)

Mineralys’s lorundrostat has demonstrated its potential to reduce blood pressure in patients with hypertension again, as the aldosterone synthase inhibitor has achieved a third clinical win in recent months giving close fight to AstraZeneca’s baxdrostat.

Key Takeaways
  • Lorundrostat met key efficacy and safety endpoints in the Phase II Explore-CKD trial, showing blood pressure and kidney benefits. 

      The biotech firm has announced positive topline data from its Phase II Explore-CKD trial evaluating the safety and efficacy of...

      Read the full article – start your free trial today!

      Join thousands of industry professionals who rely on Scrip for daily insights

      • Start your 7-day free trial
      • Explore trusted news, analysis, and insights
      • Access comprehensive global coverage
      • Enjoy instant access – no credit card required

      More from Clinical Trials

      More from Therapy Areas